Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
20 Mar 2019  |  North America
As Novel Technologies Find Traction, Industry Focus Will Shift Towards Successful Monetization to Deliver Value-based Care
he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...
20 Mar 2019  |  North America
Laboratories Seek Alternate Revenue Streams to Combat Reimbursement Pressure
Clinical laboratory services represent one of the highest healthcare expenditures in North America, yet the United States and Canada represent different scenarios in the way clinical services are rendered. The market for clinical lab services in Canada was an estimated $10.33 billion in 2017 whereas in the United States it was an estimated $78.33 b...
11 Mar 2019  |  North America
A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth
The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...
USD 2,700.00 save 10 %
07 Mar 2019  |  North America
M&As for Growth in Patient Engagement, Artificial Intelligence and Big Data Analytics are Driving Greater Vertical Integration
The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences In...
USD 2,700.00 save 10 %
11 Feb 2019  |  North America
An End-user Perspective on Laboratory Spending Reveals Modest 2019 Budget Increases Following Healthier 2018 Spending
Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...
14 Jan 2019  |  North America
Novel Applications in Oncology and Applied Sciences, Growing Research and Diagnostic Use in Developing Regions, and Automated Modular Workflows to Drive Growth
Overview: PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluct...
27 Dec 2018  |  Global
Emerging Microbiome Platforms Disrupting Pharmaceutical, Food & Beverages and the Consumer Care Industries
This research service encompasses microbiome technology trends and emerging innovations across: Disease Management This research segment explores the emerging role of microbiome-based therapeutics across a wide range of diseases, especially in the context of gastro-intestinal health, while providing strategic insights across the highly dynamic com...
13 Dec 2018  |  Africa
Unlocking Investment Potential and Improving Healthcare Delivery and Access through Policy Advancement
The West African region has a handful of emerging economies within Sub-Saharan Africa in terms of overall development and growth. The region currently has a high number of people living in extreme poverty, particularly in Nigeria, as well as a high population density. Furthermore, there has been a growing trend of non-communicable diseases, such as...
12 Dec 2018  |  North America
Innovation-as-a-service Business Model will Accelerate Growth in the Molecular Diagnostic Subsegment
Rapid technological turnaround has become a norm in the life science and in-vitro diagnostic industry. Extrinsic factors such as lack of skilled labor to operate the instrumentation as well as functional factors like demand for very high precision and reproducibility of results are driving this technological evolution. As the instrument efficiency ...
12 Nov 2018  |  Asia Pacific
Laboratory Automation is Driving the Growth of the Clinical Laboratories Market in the Country
Healthcare expenditure in Singapore is expected to grow, fueled by factors such as rising incomes and a progressively aging population. Diagnostics has emerged as a way for earlier and better identification of diseases to control rising healthcare costs in Singapore. Hence, the country has become a natural choice for many global diagnostic companie...
USD 1,275.00 save 15 %